Skip to main content
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. — Investor Relations & Filings

Ticker · CHRS ISIN · US19249H1032 LEI · 5493007IL8W5MV932D26 US Manufacturing
Open in API
Filings indexed 876 across all filing types
Latest filing 2026-06-01 Declaration of Voting R…
Country US United States of America
Listing US CHRS

About Coherus Oncology, Inc.

https://www.coherus.com/

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies. The company advances a diversified portfolio of next-generation treatments to improve outcomes for patients with cancer, particularly those with hard-to-treat tumors. Its key commercial product is LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor. LOQTORZI® is the only therapy approved by the U.S. FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), used either as a single agent or in combination with chemotherapy. Coherus's clinical pipeline includes multiple drug candidates that target the tumor microenvironment.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed pursuant to the Securities Exchange Act. It specifically contains Item 5.07 “Submission of Matters to a Vote of Security Holders” and provides the detailed voting results for each proposal at the Annual Meeting of Stockholders. This corresponds exactly to an announcement of voting outcomes, which falls under Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-06-01 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-28 English
8-K - Coherus Oncology, Inc. (0001512762) (Filer)
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” filed under the Securities Exchange Act of 1934, reporting an Item 2.02 “Results of Operations and Financial Conditions” and furnishing a press release as an exhibit. It is not the actual earnings release text itself but a regulatory filing providing notice and attaching the release. Under our taxonomy, this is a general regulatory announcement/filing (fallback) rather than the report itself or an investor presentation.
2026-05-11 English
ARS - Coherus Oncology, Inc. (0001512762) (Filer)
Annual Report
2026-04-20 English
DEF 14A - Coherus Oncology, Inc. (0001512762) (Filer)
Proxy Solicitation & Information Statement
2026-04-20 English
8-K Filing
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a stock offering, including details about the shares issued, pricing, underwriters, and lock-up agreements. It also references exhibits such as the underwriting agreement and legal opinion. This is a clear update on the company's capital raising activity and financing. It is not a full financial report, earnings release, or management discussion, but rather a specific announcement about a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2026-02-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.